Randomized trial demonstrates enhanced resistance to ceftazidime in β-lactamases, suggesting a need for revised antimicrobial strategies.
containing the P104K and P104R variants exhibited markedly increased resistance to ceftazidime, ceftazidime/avibactam, ceftazidime/relebactam, and cefiderocol, while carbapenem susceptibility remained largely unchanged. Steady-state kinetics confirmed enhanced hydrolysis of ceftazidime and cefiderocol by these variants. Molecular dynamics simulations and deep-learning analyses revealed that substitutions at position 104 alter W105 orientation, expand active-site volume, and increase hinge-loop flexibility, enabling accommodation of bulky substrates. These findings highlight the critical role of residue 104 in shaping substrate specificity and inhibitor susceptibility in KPC enzymes, with implications for antimicrobial therapy and resistance evolution.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: